publication . Article . Other literature type . 2019

Janus kinase inhibitors in immuno-inflammatory rheumatic diseases: new opportunities and prospects

Nasonov, E. L.; Lila, A. M.;
Open Access Russian
  • Published: 20 Mar 2019 Journal: Научно-практическая ревматология, volume 57, issue 1, pages 8-16 (issn: 1995-4484, eissn: 1995-4492, Copyright policy)
  • Publisher: IMA-PRESS LLC
<jats:p>Despite the great success in the diagnosis and treatment of immuno-inflammatory rheumatic diseases (IIRD), which led to a significant improvement in the prognosis in many patients, the fundamental medical problems of this pathology – the restoration of quality of life and reduction of mortality to the population level – are far from solution. This served as a powerful impetus to the study of new approaches to pharmacotherapy of IIRD, one of which is associated with the use of low-molecular synthetic drugs that inhibit intracellular "signal" molecules-Janus kinase (JAK), the socalled Jakinibs. The current achievements and trends concerning the use of JAK ...
Persistent Identifiers
free text keywords: immuno-inflammatory rheumatic diseases, cytokines, jak inhibitors, tofacitinib, lcsh:Diseases of the musculoskeletal system, lcsh:RC925-935, Tofacitinib, Synthetic drugs, Quality of life, Population level, Bioinformatics, Medicine, business.industry, business, Pharmacotherapy
Any information missing or wrong?Report an Issue